Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393915 | 1.00 | HSD11B1 (0.54) | HSD11B1HSD17B1SPHK2NPC1RAB9A | |
| SCHEMBL14741128 | 0.81 | USP2 (0.49) | LIPGRPS6KB1ACACBFFAR4 | |
| SCHEMBL1394647 | 0.80 | RPS6KB1 (0.44) | LIPGRPS6KB1BDKRB2ACACBFFAR4 | |
| SCHEMBL1393523 | 0.80 | RPS6KB1 (0.44) | LIPGRPS6KB1BDKRB2ACACBFFAR4 | |
| SCHEMBL1393176 | 0.80 | RPS6KB1 (0.44) | LIPGRPS6KB1BDKRB2ACACBFFAR4 | |
| SCHEMBL14310800 | 0.80 | RPS6KB1 (0.54) | LIPGRPS6KB1ACACBFFAR4 | |
| SCHEMBL1393331 | 0.77 | NOTUM (0.55) | HSD11B1HSD17B1 | |
| SCHEMBL1393891 | 0.77 | FFAR4 (0.41) | RPS6KB1ACACBFFAR4 | |
| SCHEMBL16568170 | 0.76 | RPS6KB1 (0.46) | SMN1; SMN2LIPGRPS6KB1ACACBFFAR4 | |
| SCHEMBL14741174 | 0.76 | BCHE (0.52) | SMN1; SMN2LIPGRPS6KB1ACACBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009968-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-14 | — | — | US | claimed |
| EP-2044073-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008006702-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-8383668-B2 | 11-beta-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383668-B2 | 11-beta-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383668-B2 | 11-beta-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-8048908-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048908-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048908-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100009968-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009968-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009968-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2044073-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006702-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006702-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885HSD17B1 4/4885SPHK2 2484/4885 |
| US-20100009968-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885SPHK2 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.